Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077

2019; Oxford University Press; Volume: 70; Issue: 2 Linguagem: Inglês

10.1093/cid/ciz439

ISSN

1537-6591

Autores

Raphael J. Landovitz, Sahar Z. Zangeneh, Gordon Chau, Beatriz Grinsztejn, Joseph J. Eron, Halima Dawood, Manya Magnus, Albert Liu, Ravindre Panchia, Mina C. Hosseinipour, Ryan Kofron, David A. Margolis, Alex R. Rinehart, Adeola Adeyeye, David Burns, Marybeth McCauley, Myron S. Cohen, Judith S. Currier,

Tópico(s)

HIV Research and Treatment

Resumo

Abstract Studies in human immunodeficiency virus (HIV)–infected individuals suggest excess weight gain with integrase inhibitor–based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.

Referência(s)